Characterization of triple negative breast cancer gene expression profiles in Mexican patients

Ortiz Valdez,Eric; Rangel‑Escareño,Claudia; Matus Santos,Juan Antonio; Vázquez Romo,Rafael; Guijosa,Alberto; Villarreal‑Garza,Cynthia; Arrieta,Oscar; Rodríguez‑Bautista,Rubén; Caro‑Sánchez,Claudia H.; Ortega Gómez,Alette

doi:10.3892/mco.2022.2601

Characterization of triple negative breast cancer gene expression profiles in Mexican patients

Authors:
- Eric Ortiz Valdez
- Claudia Rangel‑Escareño
- Juan Antonio Matus Santos
- Rafael Vázquez Romo
- Alberto Guijosa
- Cynthia Villarreal‑Garza
- Oscar Arrieta
- Rubén Rodríguez‑Bautista
- Claudia H. Caro‑Sánchez
- Alette Ortega Gómez
View Affiliations

Affiliations: Breast Tumors Department, Mexico's National Institute of Cancer, Sección XVI, Tlalpan, Mexico City 14080, Mexico, Computational Genomics Department, Instituto Nacional de Medicina Genómica, Arenal Tepepan, Tlalpan, Mexico City 14610, Mexico, School of Medicine, Universidad Panamericana, Benito Juárez, Mexico City 03920, Mexico, Breast Cancer Center, Hospital Zambrano Hellion TecSalud, Tecnológico de Monterrey, Real San Agustín, San Pedro Garza García, Nuevo León 66278, Mexico, Thoracic Oncology Unit, Mexico's National Institute of Cancer, Sección XVI, Tlalpan, Mexico City 14080, Mexico, Pathology Department, Mexico's National Institute of Cancer, Sección XVI, Tlalpan, Mexico City 14080, Mexico, Laboratory of Translational Medicine, Mexico's National Institute of Cancer, Sección XVI, Tlalpan, Mexico City 14080, Mexico
Published online on: December 15, 2022 https://doi.org/10.3892/mco.2022.2601
Article Number: 5
Copyright: © Ortiz Valdez et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Triple negative breast cancer (TNBC) is an aggressive type of cancer that accounts for ~23% of breast tumors in Mexico. In an attempt to understand in an improved way the behavior of TNBC, throughout the years, gene expression in these tumors has been studied. Lehman et al identified 6 subtypes of gene expression in TNBC with distinct characteristics. In the present study, it was aimed to assess clinical, pathological and prognostic characteristics of TNBC in a Mexican‑based cohort. A total of 55 patients diagnosed with TNBC at Mexico's National Institute of Cancer (INCan) were included. Tumor needle biopsy samples were obtained and subjected to microarray analysis. Patients were thus classified into one of the 6 TNBC molecular subtypes. The prognostic, clinical and pathological information of patients was obtained, and differences across molecular subtypes were sought. Out of the 55 included patients, the following subtypes were identified: 9 basal‑like‑1, 11 basal‑like‑2 (BSL2), 16 immunomodulatory (IM), 12 mesenchymal, 6 androgen receptor‑like and 1 mesenchymal stem‑like. Mean follow‑up time was 47.1 months. The IM molecular subtype had the best overall survival (OS) (median OS was not reached). BSL2 had the worst OS (15 months). A complete pathologic response to neoadjuvant chemotherapy was obtained more often in the IM subtype (P=0.032). No significant associations were found between any of the clinical or pathological characteristics and the TNBC molecular subtypes. The results obtained from the present study should be considered when seeking to implement a clinical‑molecular model for TNBC patient care, particularly in Hispanic‑based populations, as they have been frequently underrepresented in clinical studies assessing TNBC molecular subtypes.

View Figures

View References

1	Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 68:394–424. 2018.PubMed/NCBI View Article : Google Scholar
2	Sharma P: Biology and management of patients with triple-negative breast cancer. Oncologist. 21:1050–1062. 2016.PubMed/NCBI View Article : Google Scholar
3	Foulkes WD, Smith IE and Reis-Filho JS: Triple-negative breast cancer. N Engl J Med. 363:1938–1948. 2010.PubMed/NCBI View Article : Google Scholar
4	Reynoso-Noverón N, Villarreal-Garza C, Soto-Perez-de-Celis E, Arce-Salinas C, Matus-Santos J, Ramírez-Ugalde MT, Alvarado-Miranda A, Cabrera-Galeana P, Meneses-García A, Lara-Medina F, et al: Clinical and epidemiological profile of breast cancer in mexico: Results of the seguro popular. J Glob Oncol. 3:757–764. 2017.PubMed/NCBI View Article : Google Scholar
5	Lara-Medina F, Pérez-Sánchez V, Saavedra-Pérez D, Blake-Cerda M, Arce C, Motola-Kuba D, Villarreal-Garza C, González-Angulo AM, Bargalló E, Aguilar JL, et al: Triple-negative breast cancer in Hispanic patients. Cancer. 117:3658–3669. 2011.PubMed/NCBI View Article : Google Scholar
6	de Ruijter TC, Veeck J, de Hoon JPJ, van Engeland M and Tjan-Heijnen VC: Characteristics of triple-negative breast cancer. J Cancer Res Clin Oncol. 137:183–192. 2011.PubMed/NCBI View Article : Google Scholar
7	Kennecke H, Yerushalmi R, Woods R, Cheang MC, Voduc D, Speers CH, Nielsen TO and Gelmon K: Metastatic behavior of breast cancer subtypes. J Clin Oncol. 28:3271–3277. 2010.PubMed/NCBI View Article : Google Scholar
8	Li X, Yang J, Peng L, Sahin AA, Huo L, Ward KC, O'Regan R, Torres MA and Meisel JL: Triple-negative breast cancer has worse overall survival and cause-specific survival than non-triple-negative breast cancer. Breast Cancer Res Treat. 161:279–287. 2017.PubMed/NCBI View Article : Google Scholar
9	Martin AM, Cagney DN, Catalano PJ, Warren LE, Bellon JR, Punglia RS, Claus EB, Lee EQ, Wen PY, Haas-Kogan DA, et al: Brain metastases in newly diagnosed breast cancer: A population-based study. JAMA Oncol. 3:1069–1077. 2017.PubMed/NCBI View Article : Google Scholar
10	Xiao W, Zheng S, Yang A, Zhang X, Zou Y, Tang H and Xie X: Breast cancer subtypes and the risk of distant metastasis at initial diagnosis: A population-based study. Cancer Manag Res Volume. 10:5329–5338. 2018.PubMed/NCBI View Article : Google Scholar
11	Ignatov A, Eggemann H, Burger E and Ignatov T: Patterns of breast cancer relapse in accordance to biological subtype. J Cancer Res Clin Oncol. 144:1347–1355. 2018.PubMed/NCBI View Article : Google Scholar
12	Jin J, Gao Y, Zhang J, Wang L, Wang B, Cao J, Shao Z and Wang Z: Incidence, pattern and prognosis of brain metastases in patients with metastatic triple negative breast cancer. BMC Cancer. 18(446)2018.PubMed/NCBI View Article : Google Scholar
13	Rostami R, Mittal S, Rostami P, Tavassoli F and Jabbari B: Brain metastasis in breast cancer: A comprehensive literature review. J Neurooncol. 127:407–414. 2016.PubMed/NCBI View Article : Google Scholar
14	Kim YJ, Kim JS and Kim IA: Molecular subtype predicts incidence and prognosis of brain metastasis from breast cancer in SEER database. J Cancer Res Clin Oncol. 144:1803–1816. 2018.PubMed/NCBI View Article : Google Scholar
15	Heitz F, Harter P, Lueck HJ, Fissler-Eckhoff A, Lorenz-Salehi F, Scheil-Bertram S, Traut A and du Bois A: Triple-negative and HER2-overexpressing breast cancers exhibit an elevated risk and an earlier occurrence of cerebral metastases. Eur J Cancer. 45:2792–2798. 2009.PubMed/NCBI View Article : Google Scholar
16	Minami CA, Chung DU and Chang HR: Management options in triple-negative breast cancer. Breast Cancer (Auckl). 5:175–199. 2011.PubMed/NCBI View Article : Google Scholar
17	Kennedy BM and Harris RE: Cyclooxygenase and lipoxygenase gene expression in the inflammogenesis of breast cancer. Inflammopharmacology. 26:909–923. 2018.PubMed/NCBI View Article : Google Scholar
18	Lehmann BD, Bauer JA, Chen X, Sanders ME, Chakravarthy AB, Shyr Y and Pietenpol JA: Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest. 121:2750–2767. 2011.PubMed/NCBI View Article : Google Scholar
19	Masuda H, Baggerly KA, Wang Y, Zhang Y, Gonzalez-Angulo AM, Meric-Bernstam F, Valero V, Lehmann BD, Pietenpol JA, Hortobagyi GN, et al: Differential response to neoadjuvant chemotherapy among 7 triple-negative breast cancer molecular subtypes. Clin Cancer Res. 19(5533)2013.PubMed/NCBI View Article : Google Scholar
20	Hines LM, Risendal B, Byers T, Mengshol S, Lowery J and Singh M: Ethnic disparities in breast tumor phenotypic subtypes in hispanic and non-hispanic white women. J Womens Health. 20:1543–1550. 2011.PubMed/NCBI View Article : Google Scholar
21	Yin L, Duan JJ, Bian XW and Yu S: Triple-negative breast cancer molecular subtyping and treatment progress. Breast Cancer Res. 22(61)2020.PubMed/NCBI View Article : Google Scholar
22	Fitzgibbons PL, Dillon DA, Alsabeh R, Berman MA, Hayes DF, Hicks DG, Hughes KS and Nofech-Mozes S: Template for reporting results of biomarker testing of specimens from patients with carcinoma of the breast. Arch Pathol Lab Med. 138:595–601. 2014.PubMed/NCBI View Article : Google Scholar
23	Rodríguez-Bautista R, Caro-Sánchez CH, Cabrera-Galeana P, Alanis-Funes GJ, Gutierrez-Millán E, Ávila-Ríos S, Matías-Florentino M, Reyes-Terán G, Díaz-Chávez J, Villarreal-Garza C, et al: Immune Milieu and genomic alterations set the triple-negative breast cancer immunomodulatory subtype tumor behavior. Cancers (Basel). 13(6256)2021.PubMed/NCBI View Article : Google Scholar
24	RStudio Team: RStudio: Integrated Development of R., 2021.
25	Marini F, Linke J and Binder H: Ideal: An R/Bioconductor package for Interactive differential expression analysis. BMC Bioinformatics. 21(565)2020.PubMed/NCBI View Article : Google Scholar
26	Bolstad BM, Irizarry RA, Åstrand M and Speed TP: A comparison of normalization methods for high density oligonucleotide array data based on variance and bias. Bioinformatics. 19:185–193. 2003.PubMed/NCBI View Article : Google Scholar
27	Irizarry RA, Hobbs B, Collin F, Beazer-Barclay YD, Antonellis KJ, Scherf U and Speed TP: Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics. 4:249–264. 2003.PubMed/NCBI View Article : Google Scholar
28	Banerji S, Cibulskis K, Rangel-Escareno C, Brown KK, Carter SL, Frederick AM, Lawrence MS, Sivachenko AY, Sougnez C, Zou L, et al: Sequence analysis of mutations and translocations across breast cancer subtypes. Nature. 486:405–409. 2012.PubMed/NCBI View Article : Google Scholar
29	Johnson WE, Li C and Rabinovic A: Adjusting batch effects in microarray expression data using empirical Bayes methods. Biostatistics. 8:118–127. 2007.PubMed/NCBI View Article : Google Scholar
30	Parker JS, Mullins M, Cheang MCU, Leung S, Voduc D, Vickery T, Davies S, Fauron C, He X, Hu Z, et al: Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol. 27:1160–1167. 2009.PubMed/NCBI View Article : Google Scholar
31	Bareche Y, Venet D, Ignatiadis M, Aftimos P, Piccart M, Rothe F and Sotiriou C: Unravelling triple-negative breast cancer molecular heterogeneity using an integrative multiomic analysis. Ann Oncol. 29:895–902. 2018.PubMed/NCBI View Article : Google Scholar
32	Hubalek M, Czech T and Müller H: Biological subtypes of triple-negative breast cancer. Breast Care. 12:8–14. 2017.PubMed/NCBI View Article : Google Scholar
33	Brosnan EM and Anders CK: Understanding patterns of brain metastasis in breast cancer and designing rational therapeutic strategies. Ann Transl Med. 6:163. 2018.PubMed/NCBI View Article : Google Scholar
34	Quattrocchi CC, Errante Y, Gaudino C, Mallio CA, Giona A, Santini D, Tonini G and Zobel BB: Spatial brain distribution of intra-axial metastatic lesions in breast and lung cancer patients. J Neurooncol. 110:79–87. 2012.PubMed/NCBI View Article : Google Scholar
35	Lv Y, Ma X, Du Y and Feng J: Understanding patterns of brain metastasis in triple-negative breast cancer and exploring potential therapeutic targets. Onco Targets Ther. 14:589–607. 2021.PubMed/NCBI View Article : Google Scholar